Anti-PD-(L)1 therapy of non-small cell lung cancer–A summary of clinical trials and current progresses

BACKGROUND: This review discusses the impact of mono or combination therapy of immune checkpoint inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC) patients, comparing clinical outcomes and safety. Cancer subtype, tumor mutational burden (TMB), programmed death-ligand 1 (PD-L1) expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Mortezaee, Keywan, Majidpoor, Jamal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025922/
https://www.ncbi.nlm.nih.gov/pubmed/36950599
http://dx.doi.org/10.1016/j.heliyon.2023.e14566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025922/
https://www.ncbi.nlm.nih.gov/pubmed/36950599
http://dx.doi.org/10.1016/j.heliyon.2023.e14566

Ejemplares similares